Aspartic acid
- Generic Name
- Aspartic acid
- Brand Names
- Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %
- Drug Type
- Small Molecule
- Chemical Formula
- C4H7NO4
- CAS Number
- 56-84-8
- Unique Ingredient Identifier
- 30KYC7MIAI
- Background
One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
- Indication
There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.
- Associated Therapies
- Amino acid supplementation
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Sapacitabine, Arm ADrug: Sapacitabine, Arm BDrug: Sapacitabine, Arm CDrug: sapacitabine, Arm EDrug: Sapacitabine, Arm GDrug: Sapacitabine, Arm HDrug: Sapacitabine, Arm I
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT00590187
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Vanderbilt U Medical Center, Nashville, Tennessee, United States
Staccato Loxapine Multidose PK
- Conditions
- Volunteers on Chronic, Stable Antipsychotic Regimens
- Interventions
- Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total)Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total)
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00555412
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT00548769
- Locations
- 🇵🇱
GSK Investigational Site, Poznan, Poland
A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Treatment sequence CDrug: Treatment sequence ADrug: Treatment sequence B
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 81
- Registration Number
- NCT00537654
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Bioequivalence and Food Effect Study in Healthy Volunteers
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: Formulation ADrug: Formulation BDrug: Formulation CDrug: Formulation EDrug: Formulation G
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00495274
- Locations
- 🇮🇹
GSK Investigational Site, Verona, Veneto, Italy
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2011-07-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 604
- Registration Number
- NCT00404820
- Locations
- 🇩🇪
For site information contact Novartis Pharmaceuticals, Multiple Cities, Germany
Optimizing Vitamin D Nutrition in Healthy Adults
- Conditions
- Vitamin D Deficiency
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- Winthrop University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT00327847
- Locations
- 🇺🇸
Winthrop University Hospital, Mineola, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.